Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive
Does the drug delivery system, TAR-200, safe and tolerable in patients with bladder
Basic Study Information
Purpose:Location: University of Rochester Medical Center
The purpose of this study is to determine if TAR-200, an investigational drug delivery
system, in combination with nivolumab, is safe and tolerable in patients with muscle-invasive
bladder cancer (MIBC) who are scheduled for radical cystectomy (RC).
Study Contact InformationStudy Coordinator: Peter MacDowell
Phone: (585) 276-3450
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search